Brief: Bergenbio: First Covid19 Patient Dosed With Bemcentinib In Accord Trial

Oncoinvent ASA

02/06/2020 06:02

June 2 (Reuters) - Bergenbio ASA  BGBIO.OL :
    * BERGENBIO CONFIRMS FIRST COVID19 PATIENT DOSED WITH
BEMCENTINIB
IN ACCORD TRIAL
    * STUDY IS FULLY FUNDED BY DHSC AND UKRI AND IS BEING
MANAGED BY
CLINICAL RESEARCH COMPANY IQVIA. DRUG MATERIAL AND OTHER TRIAL
RESOURCES WILL BE PROVIDED BY BERGENBIO
    * ANTICIPATES THAT TOP LINE DATA WILL READOUT LATER IN
SUMMER

Source text for Eikon:  ID:nWkr1nQQZw 
Further company coverage:  BGBIO.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))